Recently, Huzhou Science and Technology Bureau announced the “List of the First Batch of Municipal-level Science and Technology Enterprise Research and Development Center in 2021”, and the “TYK Medicines’ Targeted Anti-tumor Innovative Drug Municipal Science and Technology Enterprise Research and Development Center” was successfully selected. Rely on the municipal-level science and technology enterprise research and development center, our company will establish professional laboratories, introduce talents, conduct further in-depth research in the comprehensive utilization of resources, increase investment, accelerate the transformation of intellectual property rights, and enhance the enterprise’s independent innovation ability and core competitiveness.

About TYK Medicines, Inc

TYK Medicines, Inc. was established in November 2017 in Life Science Park Changxing Economic Development Zone. The company is an innovative biotechnology company, based in China with a global presence focusing on cutting-edge innovative drug research and development. The company has established a highly effective innovative drug research and development platform with fully equipped world-class instruments, covering drug synthesis, microbial fermentation, drug analysis, biological analysis, formulation research, etc. The company committee to become the best domestically and world-class new drug research and development company.

High-tech talents are the cornerstone to support the rapid development of TYK Medicines. Since its establishment, the company has been vigorously introducing high-end talents domestically and globally, and up to now, the company has set up a world-class R&D and management team with more than 150 team members, including one national-level expert, four Zhejiang provincial-level experts, three Zhejiang provincial-level overseas engineers, more than 10 doctoral returnees with rich experience in new drug R&D in well-known multinational pharmaceutical companies, and more than 80% of employees with master’s degree or above. The team has formed a strong R&D team in the whole industry chain of innovative drug R&D from new drug design, new drug screening, new drug synthesis, and new drug clinical to new drug production, covering many fields such as pharmacology, chemistry, biology, formulation, pharmacokinetics, pharmacodynamics, and clinical research.

Based on the unmet medical needs for new drugs for major diseases in China and closely following the international new drug research and development hotspots, the R&D team of TYK Medicines has invested nearly 30,000,000 yuan in R&D and carried out more than 10 new targeted anti-tumor drug projects, among which one national chemical 1.1 class new drug project has obtained clinical approval from FDA and two national chemical 1.1 class new drug projects have obtained approval from NMPA, all of which are currently in clinical trials. In addition, the company has several global potential First-in-class innovative drug projects in progress, and some of them have completed the identification of clinical candidates and are ready to enter the PCC stage. Up to now, the company has applied for 41 patents for new drug-related inventions and 8 PCT patents, of which 6 domestic patents have been granted and 1 US patent has been granted.

In addition, TYK Medicines attaches great importance to the construction of provincial and municipal scientific research institutions, and actively participates in national, provincial, and municipal scientific and technological projects. The details are as follows:

In May 2019, the company introduced Yangjie Wu Academician of the Chinese Academy of Sciences to set up the Huzhou Academician Expert Workstation.

In October 2019, TYK Medicines’ new drug research and development team was rated as a leading entrepreneurial team in the “South Taihu Lake Elite Program” in Huzhou City. In the same year, the company was awarded as a science and technology-based small and medium-sized enterprise in Zhejiang Province and a national science and technology-based small and medium-sized enterprise.

In 2020, the company’s innovative drug development project was awarded as one of the key R&D projects in Zhejiang Province (Merit-based project), a special biomedical project in Huzhou City, and a key technological innovation project in Zhejiang Province.

In 2021, 2 of the company’s innovative drug projects were selected as Foreign Expert Projects by the Ministry of Science and Technology and 1 innovative drug project was selected as a key technological innovation project in Zhejiang Province.

TYK Medicines’ strong R&D talent lineup and excellent new drug projects have attracted much attention from the industry. In the past 4 years, the company has received several venture capital investments in its research projects. In May 2018, the company completed an angel round of financing of 47 million yuan led by BioTrack Capital. In April 2019, the company completed a Pre-A round of financing of 50 million yuan led by Tengyuan Investment to support the preclinical research projects conducted by the company as well as other projects under development. In August 2020, TYK Medicines licenses out the greater China rights and interests of the targeted anti-lung cancer drug TY-2136b to Livzon Group, a listed company, and obtained a cooperation fund of 159 million yuan. In December 2020, the company obtained 260 million yuan in Series B financing led by Yida Capital. In May 2021, the company received a 400 million yuan B+ round of financing led by Sealand Innovation Capital. So far, TYK Medicine has successfully raised nearly 1 billion yuan.